Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer-Reference-Cited by-同舟云学术

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer

Published:2018-08-31 Issue:5 Volume:38 Page:656-670
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Yochum Zachary A.,Cades Jessica,Wang Hailun,Chatterjee Suman,Simons Brian W.^ORCID,O’Brien James P.,Khetarpal Susheel K.,Lemtiri-Chlieh Ghali,Myers Kayla V.,Huang Eric H.-B.,Rudin Charles M.^ORCID,Tran Phuoc T.^ORCID,Burns Timothy F.

Funder

American Lung Association

V Foundation for Cancer Research

Sidney Kimmel Foundation for Cancer Research

Doris Duke Charitable Foundation

U.S. Department of Health & Human Services | NIH | National Cancer Institute

We Wish Foundation

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences

Howard Hughes Medical Institute

Uniting Against Lung Cancer Foundation

U.S. Department of Defense

American Cancer Society

Nesbitt Family; Uniting Against Lung Cancer Foundation; Movember-Prostate Cancer Foundation; Commonwealth Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0482-y.pdf

Reference60 articles.

1. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.

2. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006.

3. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.

4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

5. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17:1160–8.

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer;Cell Death & Disease;2024-09-03

2. Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance;Drug Resistance Updates;2024-09

3. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up;Oncogene;2024-08-15

4. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

5. Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC);Cancer Pathogenesis and Therapy;2024-07